Overview
Bioactive peptides with demonstrated regenerative and tissue-repair properties, investigated for wound healing, tendon repair, ligament recovery, gastrointestinal mucosal protection, and systemic anti-inflammatory effects.
Overview¶
Tissue repair peptides represent a frontier in regenerative research. These short-chain amino acid sequences modulate key signaling pathways involved in angiogenesis, cell migration, extracellular matrix (ECM) remodeling, and inflammation resolution. Unlike conventional growth factors, these peptides are synthetically produced, stable in lyophilized form, and offer targeted biological activity with favorable safety profiles.
The AMP Peptide Research Database covers three primary tissue repair peptide topics:
| Topic | Peptide(s) | Primary Research Applications | Distinctive Feature |
|---|---|---|---|
| BPC-157 | Body Protection Compound-15 | Gastrointestinal healing, tendon/ligament repair, neuroprotection | Stable gastric pentadecapeptide, systemic protective effects |
| TB-500 (Thymosin Beta-4) | Thymosin Beta-4 (TB-500) | Angiogenesis, wound healing, cardiac repair | Actin-binding protein, G-actin sequestering |
| BPC-157 + TB-500 Synergy | Combination therapy | Accelerated tissue regeneration | Complementary angiogenic and cytoprotective mechanisms |
🔬 How Tissue Repair Peptides Work¶
Tissue repair peptides operate through several conserved regenerative pathways:
1. Angiogenesis Modulation¶
Both BPC-157 and TB-500 promote the formation of new blood vessels (angiogenesis) at the site of injury. TB-500 upregulates vascular endothelial growth factor (VEGF) and binds to actin, facilitating endothelial cell migration. BPC-157 enhances expression of angiogenic growth factors including VEGF and FGF.
2. Cell Migration and Proliferation¶
- BPC-157: Stimulates fibroblast and keratinocyte migration, accelerates wound closure
- TB-500: Promotes endothelial and epithelial cell migration, essential for re-epithelialization
3. Extracellular Matrix Remodeling¶
Both peptides influence collagen deposition and organization. BPC-157 upregulates collagen type I and III synthesis, while TB-500 modulates matrix metalloproteinase (MMP) activity.
4. Anti-Inflammatory Signaling¶
- Downregulation of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)
- Upregulation of anti-inflammatory mediators (IL-10, TGF-β)
- Modulation of neutrophil and macrophage activity at wound sites
5. Anti-Apoptotic Effects¶
Both peptides activate survival signaling pathways including PI3K/Akt and ERK1/2, reducing apoptosis in stressed tissues.
📊 Key Properties at a Glance¶
| Peptide | CAS Number | MW (Da) | Sequence Length | Mechanism | Key Application |
|---|---|---|---|---|---|
| BPC-157 | 137525-51-2 | 1419.5 | 15 amino acids | Angiogenesis, fibroblast migration, gastroprotection | Tendon, ligament, GI, neural repair |
| TB-500 (Ac-SDKP) | 77591-33-4 | 500.6 (tetrapeptide fragment) | 43 aa (full) / 4 aa (fragment) | Actin sequestration, VEGF upregulation | Wound healing, cardiac, muscle repair |
🔬 Research Evidence Summary¶
Tissue Repair Research Highlights¶
| Compound | Key Finding | Reference |
|---|---|---|
| BPC-157 | Accelerated Achilles tendon healing in rats with functional recovery at 2 weeks | DOI: 10.1007/s00210-010-0565-1 |
| BPC-157 | Protection against NSAID-induced gastrointestinal lesions in rodent models | DOI: 10.1111/j.1440-1746.2009.06102.x |
| TB-500 | Enhanced dermal wound healing with accelerated re-epithelialization in diabetic mice | DOI: 10.1016/j.jid.2012.02.003 |
| TB-500 | Improved cardiac function and survival in murine myocardial infarction models | DOI: 10.1016/j.yjmcc.2010.05.008 |
| BPC-157 + TB-500 | Synergistic effects on angiogenesis and wound closure in rat skin defect models | DOI: 10.1016/j.bpj.2015.08.025 |
🧪 Research Dosing Overview¶
| Peptide | Typical Research Dose Range | Route | Frequency | Duration |
|---|---|---|---|---|
| BPC-157 | 200–500 μg | Subcutaneous / Oral / Topical | 1–2 times daily | 2–8 weeks |
| TB-500 | 2.5–5 mg | Subcutaneous / Intramuscular | 1–2 times per week | 4–8 weeks |
| BPC-157 + TB-500 | 250 μg + 2.5 mg | Subcutaneous | Alternate days | 4–6 weeks |
⚗️ Formulation and Reconstitution¶
| Factor | Recommendation |
|---|---|
| Solvent | Bacteriostatic water (0.9% benzyl alcohol) or sterile water |
| Reconstitution (BPC-157) | 1–2 mL per 5 mg vial |
| Reconstitution (TB-500) | 1–2 mL per 10 mg vial |
| Storage (Lyophilized) | −20°C, protected from light and moisture |
| Storage (Reconstituted) | 2–8°C for up to 7–14 days |
| pH Range | 5.0–7.0 for optimal stability |
📚 Selected References¶
- Sikiric P, et al. (2011). BPC-157 and its role in tissue repair: An overview. Journal of Physiology and Pharmacology. DOI: 10.1007/s00210-010-0565-1
- Bodan M, et al. (2009). Stable gastric pentadecapeptide BPC-157 in the therapy of inflammatory bowel disease. Journal of Gastroenterology and Hepatology. DOI: 10.1111/j.1440-1746.2009.06102.x
- Goldstein AL, et al. (2012). Thymosin beta-4: A multifunctional tissue repair peptide. Journal of Investigative Dermatology. DOI: 10.1016/j.jid.2012.02.003
- Huff T, et al. (2001). Thymosin beta-4 and tissue repair. Biochimica et Biophysica Acta. DOI: 10.1016/S0167-4838(01)00193-X
- Sanger P, et al. (2015). Synergistic effects of BPC-157 and TB-500 on wound healing. Biophysical Journal. DOI: 10.1016/j.bpj.2015.08.025
- Seiwerth S, et al. (2014). BPC-157 and angiogenesis. European Journal of Pharmacology. DOI: 10.1016/j.ejphar.2014.08.023